FAQs for PrEPVacc's vaccine result
Media coverage of PrEPVacc's July 2024 vaccine result announcement
Taarifa kwa Umma: Chanjo za VVU zilizojaribiwa katika utafiti wa PrEPVacc zashindwa kupunguza maambukizi
News Release: HIV vaccines tested in PrEPVacc fail to reduce infections
AIDS 2024: “I am not sick, why should I swallow daily pills?”: non-uptake of, and adherence to daily oral pre-exposure prophylaxis among adults at high-risk of HIV in Masaka, Uganda
AIDS 2024: Knowledge and experiences of participating in an HIV vaccine efficacy trial with second randomization to oral pre-exposure prophylaxis in South Africa, Tanzania, and Uganda
AIDS 2024: HIV risk perception, trust and PrEP adherence among participants in an HIV prevention trial: a qualitative longitudinal study, South Africa
AIDS 2024: Disclosing of Participation in an HIV Vaccine Trial in Southwestern Uganda – the effect on participant engagement
AVAC briefing on PrEPVacc: An in-depth look at the trial, and what’s next
Media coverage of PrEPVacc's December 2023 study update
News Release: Experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition, PrEPVacc study reports
STAT: 'Can the world still invent an HIV vaccine? Progress in one area creates new problem'
CNN reports on ‘the last roll of the dice’ for an HIV vaccine this decade
News Release: African-led PrEPVacc HIV prevention study completes its enrolment
Video to help inform PrEPVacc participants posted online
Examining oral pre-exposure prophylaxis (PrEP) literacy among participants in an HIV vaccine trial preparedness cohort study
PrEPVacc announces enrolment ‘almost complete’ during World AIDS Day 2022
Attitudes towards PrEP uptake and adherence explored in Masaka, Uganda
Getty photographer visits PrEPVacc site at Masaka
PrEPVacc featured in December 2021 'Science et Vie' magazine cover story
